Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).

Donini, M

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). [electronic resource] - Targeted oncology Jun 2015 - 277-86 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1776-260X

10.1007/s11523-014-0337-6 doi


Administration, Intravenous
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Antimetabolites, Antineoplastic--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Bevacizumab--administration & dosage
Carcinoma, Renal Cell--drug therapy
Cell Separation--methods
Chemotherapy, Adjuvant
Deoxycytidine--administration & dosage
Disease Progression
Disease-Free Survival
Female
Flow Cytometry
Fluorouracil--administration & dosage
Humans
Immunotherapy--adverse effects
Interferon alpha-2
Interferon-alpha--administration & dosage
Interleukin-2--administration & dosage
Italy
Kaplan-Meier Estimate
Kidney Neoplasms--drug therapy
Male
Middle Aged
Nephrectomy
Recombinant Proteins--administration & dosage
T-Lymphocytes, Regulatory--drug effects
Time Factors
Treatment Outcome
Gemcitabine